T. Ruijs

Transcranial magnetic stimulation as biomarker of excitability in drug development: A randomized, double‐blind, placebo‐controlled, cross‐over study

M. V. van Putten, G. Groeneveld, R. Doll, 2022, British journal of clinical pharmacology.

Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study

M. D. de Kam, M. Tannemaat, G. Groeneveld, 2022, Clinical and translational science.

Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulation

D. Buhl, P. O’Donnell, A. Rotenberg, 2021, Translational Psychiatry.

Effects of Mexiletine and Lacosamide on Nerve Excitability in Healthy Subjects: A Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study

M. Koltzenburg, M. D. de Kam, G. Groeneveld, 2022, Clinical pharmacology and therapeutics.

Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction

D. Webb, J. Dear, S. Chandran, 2016, JCI insight.

The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis

M. D. de Kam, G. Groeneveld, J. Heuberger, 2024, Science Translational Medicine.